JP2015505314A - アルツハイマー病を治療する方法及び医薬品 - Google Patents

アルツハイマー病を治療する方法及び医薬品 Download PDF

Info

Publication number
JP2015505314A
JP2015505314A JP2014551232A JP2014551232A JP2015505314A JP 2015505314 A JP2015505314 A JP 2015505314A JP 2014551232 A JP2014551232 A JP 2014551232A JP 2014551232 A JP2014551232 A JP 2014551232A JP 2015505314 A JP2015505314 A JP 2015505314A
Authority
JP
Japan
Prior art keywords
subject
pioglitazone
alzheimer
disease
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014551232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505314A5 (enExample
Inventor
アレン ディー． ローゼス
アレン ディー． ローゼス
ラジニーシ タネージャ
ラジニーシ タネージャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/346,081 external-priority patent/US9102666B2/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2015505314A publication Critical patent/JP2015505314A/ja
Publication of JP2015505314A5 publication Critical patent/JP2015505314A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2014551232A 2012-01-09 2012-07-13 アルツハイマー病を治療する方法及び医薬品 Pending JP2015505314A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/346,081 2012-01-09
USPCT/US2012/020606 2012-01-09
US13/346,081 US9102666B2 (en) 2011-01-10 2012-01-09 Methods and drug products for treating Alzheimer's disease
PCT/US2012/020606 WO2012096873A1 (en) 2011-01-10 2012-01-09 Methods and drug products for treating alzheimer's disease
US201261659872P 2012-06-14 2012-06-14
US61/659,872 2012-06-14
PCT/US2012/046692 WO2013106084A1 (en) 2012-01-09 2012-07-13 Methods and drug products for treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017111243A Division JP2017197554A (ja) 2012-01-09 2017-06-06 アルツハイマー病を治療する方法及び医薬品

Publications (2)

Publication Number Publication Date
JP2015505314A true JP2015505314A (ja) 2015-02-19
JP2015505314A5 JP2015505314A5 (enExample) 2015-09-03

Family

ID=48781795

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014551232A Pending JP2015505314A (ja) 2012-01-09 2012-07-13 アルツハイマー病を治療する方法及び医薬品
JP2017111243A Pending JP2017197554A (ja) 2012-01-09 2017-06-06 アルツハイマー病を治療する方法及び医薬品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017111243A Pending JP2017197554A (ja) 2012-01-09 2017-06-06 アルツハイマー病を治療する方法及び医薬品

Country Status (2)

Country Link
JP (2) JP2015505314A (enExample)
WO (1) WO2013106084A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017001989A (ja) * 2015-06-11 2017-01-05 ニプロ株式会社 医薬組成物の製造方法及び医薬組成物
JP2021529748A (ja) * 2018-06-27 2021-11-04 コルデイロ マリア フランチェスカＣＯＲＤＥＩＲＯ， Ｍａｒｉａ Ｆｒａｎｃｅｓｃａ 組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160345855A1 (en) * 2013-12-13 2016-12-01 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536294A (ja) * 1998-11-27 2002-10-29 ケース ウェスタン リザーブ ユニバーシティ アルツハイマー病、中枢神経系の損傷および炎症性疾患を治療するための組成物ならびに方法
JP2012500004A (ja) * 2008-08-12 2012-01-05 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
JP2014505055A (ja) * 2011-01-10 2014-02-27 ジンファンデル ファーマシューティカルズ インコーポレイテッド アルツハイマー病を治療するための方法及び製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536294A (ja) * 1998-11-27 2002-10-29 ケース ウェスタン リザーブ ユニバーシティ アルツハイマー病、中枢神経系の損傷および炎症性疾患を治療するための組成物ならびに方法
JP2012500004A (ja) * 2008-08-12 2012-01-05 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
JP2014505055A (ja) * 2011-01-10 2014-02-27 ジンファンデル ファーマシューティカルズ インコーポレイテッド アルツハイマー病を治療するための方法及び製剤
JP2017014296A (ja) * 2011-01-10 2017-01-19 ジンファンデル ファーマシューティカルズ インコーポレイテッド アルツハイマー病を治療するための方法及び製剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARCH. NEUROL., 2010, VOL.67, NO.5, P.536-541, JPN6015044284, ISSN: 0003308991 *
BRAIN, 2005, VOL.128, P.1442-1453, JPN6015044280, ISSN: 0003308989 *
ENDOCR J., 2006, VOL.53, NO.3, P.325-330, JPN6015044278, ISSN: 0003308987 *
NEUROBIOL AGING, 2011(AVAILABLE ONLINE:2009 NOV 17), VOL.32, NO.9, P.1626-1633, JPN6015044288, ISSN: 0003308988 *
PHARMACOGENOMICS J., 2010, VOL.10, NO.5, P.375-384, JPN6015044282, ISSN: 0003308990 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017001989A (ja) * 2015-06-11 2017-01-05 ニプロ株式会社 医薬組成物の製造方法及び医薬組成物
JP2021529748A (ja) * 2018-06-27 2021-11-04 コルデイロ マリア フランチェスカＣＯＲＤＥＩＲＯ， Ｍａｒｉａ Ｆｒａｎｃｅｓｃａ 組成物
JP7583615B2 (ja) 2018-06-27 2024-11-14 マリア フランチェスカ コルデイロ 組成物

Also Published As

Publication number Publication date
WO2013106084A1 (en) 2013-07-18
JP2017197554A (ja) 2017-11-02

Similar Documents

Publication Publication Date Title
JP6745304B2 (ja) アルツハイマー病を治療するための方法及び製剤
JP2022009066A (ja) Ｓ－エコールを用いてアルツハイマー病を診断するおよび治療する方法
JP2017197554A (ja) アルツハイマー病を治療する方法及び医薬品
JP2019515004A (ja) Ａｐｐの正常なプロセシングを促進する化合物
AU2013204550B2 (en) Methods and drug products for treating alzheimer's disease
JP2018505899A (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
NZ611948B2 (en) Methods and drug products for treating alzheimer's disease
US20240409928A1 (en) Novel rna transcript
HK1189825A (en) Methods and drug products for treating alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170207